Moderna mRNA vaccine reduces return of melanoma by 44%

Investment Analysis Clubs Macro Economic Trends and Risks
1

The randomized trial included 157 patients with stage 3 or stage 4 melanoma who had already had surgery. Some patients received nine doses of the experimental cancer vaccine made by Moderna and the immunotherapy made by Merck every three weeks for about a year, and some received only the immunotherapy. Treatment with the experimental vaccine in combination with the immunotherapy reduced the risk of cancer recurrence or death by 44% compared with the immunotherapy alone, the companies said.

Jeff
(Disclosure: Looked up why my portfolio was out-performing today :slight_smile: )

5 Likes
2

Dyslexia is fun department: first time through, I read that as “recurrence of death”, and went “what?”

I wouldn’t bet the farm on a “study” of only 157 people. That being said, I saw an interview, a couple years ago, of the two people behind BioNTech, talking about using their mRNA technology to target specific cancers. BNTX is up 7% today.

Steve

2 Likes
3

I just hope there isn’t any incidence of sudden cardiac arrest/death syndrome like we are seeing right now around the world…doc

2 Likes
4

MRNA was up 20% today. A poster child for the opportunity cost of selling covered calls.

DB2

5

Jeff,

I am indebted. I sent this to one of my sisters who has a first sign of melanoma about three years ago.

6

You mean like the incidence of side effects with the smallpox (cow pox) vaccine?:sweat_smile::rofl::joy: … :thinking:

The cow-pock,-or-The wonderful effects of the new inoculation! | The Morgan Library & Museum

7

Small numbers and early days for sure…but not in and of itself unduly suspicious. What does wave an honkin’ big Flamme Rouge, however, is the statement to the effect that these are the results of a phase 2b study that come from a press release that hasn’t yet been peer reviewed or even published. How much more unethical can you get?

1 Like
8

That is how Moderna rolls. Remember the release of preliminary findings of a trial of Moderna’s covid vax, just in time to goose the stock, for the company’s benefit?

When the biotech company Moderna announced early on Monday morning positive results from a small, preliminary trial of its [coronavirus vaccine], the company’s chief medical officer described the news as a “triumphant day for us.”

Moderna’s stock price jumped as much as 30 percent.

Nine hours after its initial news release — and after the markets closed — the company announced a stock offering with the aim of raising more than $1 billion to help bankroll vaccine development. That offering had not been mentioned in Moderna’s briefings of investors and journalists that morning, and the company chairman later said it was decided on only that afternoon.